Skip to content
value.today

CV Sciences, Inc.

CVSI
$20 Mlast known market cap, Jan 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
$14 M
For year ending December-2025
Net income
$-1 M
-7.0% margin
SEC filing
Employees
44
As of December 31, 2025
SEC filing

CV Sciences, Inc. in brief

CV Sciences, Inc. is a listed company in the Pharmaceutical industry, based in San Diego, California, USA. It was founded in 2010. Its last known market value was $20 M (January 2022); there is no current figure. In the year to December 2025 it had sales of $14 M and a net loss of $1 M. It employs about 44 people.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About CV Sciences, Inc.

CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods. Our hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business to business-to-consumer.

Our +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe status.

From the company's annual report filed with the US SEC: read the report

CV Sciences, Inc. timeline

5 events, 2010–2019
  1. 2010
  2. 🏁
    · approximate
    Founded
  3. 2011
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2012
  6. ✎
    Renamed CannaVEST Corp.
    Formerly Foreclosure Solutions, Inc..
  7. 2016
  8. ✎
    Renamed CV Sciences, Inc.
    Formerly CannaVEST Corp..
  9. 2019
  10. 💰
    Record revenue of $54 million
    FY2019, the highest of the 8 years on record.

Events of CV Sciences, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$28 M$56 M$84 M$112 M202020212022

World rank over time

▼ down 11,823 places since 2020
2020-01-01: #18704#18,70420202021-01-01: #20848#20,84820212022-01-07: #30527#30,5272022

Rank in USA: #3,677 (Jan 2020) · #4,094 (Jan 2021) · #5,391 (Jan 2022)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-15.8%
Operating margin
-3.4%
Return on equity
-136.7%
Liabilities / assets
78.9%
Net debt
$1M
Revenue growth
-12.2%
R&D / revenue
0.9%
Revenue per employee
$313 K
Profit per employee
$-22 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $48M, net income $10M$48MFY18Fiscal year ending Dec 2019: revenue $54M, net income $-17M$54MFY19Fiscal year ending Dec 2020: revenue $24M, net income $-22M$24MFY20Fiscal year ending Dec 2021: revenue $20M, net income $-16M$20MFY21Fiscal year ending Dec 2022: revenue $16M, net income $-8M$16MFY22Fiscal year ending Dec 2023: revenue $16M, net income $3M$16MFY23Fiscal year ending Dec 2024: revenue $16M, net income $-2M$16MFY24Fiscal year ending Dec 2025: revenue $14M, net income $-1M$14MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$14M-12.2%$-0M$-1M-7.0%
Dec 2024$16M-1.9%$-2M$-2M-15.2%
Dec 2023$16M-1.2%$3M$3M19.4%
Dec 2022$16M-19.2%$-7M$-8M-50.7%
Dec 2021$20M-17.9%$-18M$-16M-77.6%
Dec 2020$24M-54.5%$-23M$-22M-91.2%
Dec 2019$54M+11.3%$-17M$-17M-30.9%
Dec 2018$48M—$10M$10M20.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-0M$0M$-1M$-0.01—
Dec 2024$-1M$0M$-1M$-0.01—
Dec 2023$2M$0M$2M$0.02—
Dec 2022$-2M$0M$-2M$-0.07—
Dec 2021$-7M$0M$-8M$-0.14—
Dec 2020$-7M$1M$-8M$-0.22—
Dec 2019$-2M$1M$-3M$-0.17—
Dec 2018$13M$1M$12M$0.09—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$13M
Net income, trailing 12 months
$-2M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $4M, net income $-1M$4MDec ’24Three months to Mar 2025: revenue $4M, net income $-0M$4MMar ’25Three months to Jun 2025: revenue $4M, net income $-0M$4MJun ’25Three months to Sep 2025: revenue $3M, net income $-0M$3MSep ’25Three months to Dec 2025 (from the annual report): revenue $3M, net income $-0M$3MDec ’25Three months to Mar 2026: revenue $3M, net income $-1M$3MMar ’26Three months to Jun 2026: revenue $3M, net income $-1M$3MJun ’26Three months to Sep 2026: revenue $3M, net income $-0M$3MSep ’26

Latest quarter to Sep 2026: revenue $3M (-7.1% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of CV Sciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$14 M
Operating income
$-0 M
Net income
$-1 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$7 M
Total liabilities
$5 M
Total equity
$1 M

As of December-2025

Insider trading at CV Sciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$169 K
15 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$169 K
open market only
Insiders on file
15
since
$111 K$0Jul 2026: bought $111 K (8 trades), sold $0 (0 trades)Jul 26Aug 2026: bought $4 K (2 trades), sold $0 (0 trades)AugNov 2026: bought $54 K (5 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
CV Sciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Charlie E. Cheever III10% ownerBuy+383,205$0.010$4 K32.09 MForm 4
filed Charlie E. Cheever III10% ownerBuy+1.98 M$0.010$20 K31.71 MForm 4
filed Charlie E. Cheever III10% ownerBuy+500,000$0.010$5 K29.73 MForm 4
filed Charlie E. Cheever III10% ownerBuy+1.08 M$0.010$11 K29.23 MForm 4
filed Charlie E. Cheever III10% ownerBuy+1.50 M$0.010$15 K28.15 MForm 4
filed Charlie E. Cheever III10% ownerBuy+94,854$0.020$2 K26.65 MForm 4
filed Charlie E. Cheever III10% ownerBuy+108,000$0.020$2 K26.55 MForm 4
filed Charlie E. Cheever III10% ownerBuy+1.73 M$0.020$35 K26.45 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

CV Sciences, Inc. scorecard#

Passes 3 of the 15 checks that could be worked out: strongest in financial health (1 of 3), weakest in growth (1 of 6). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-12.2%Revenue down 12.2% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-5.2%-5.2% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-5.2%-5.2% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year-0.01 vs -0.01Diluted EPS -0.01 in fiscal 2025 against -0.01 the year before (report's currency).
    • ✓Net income higher than five years earlier-$1 M-$1 M in fiscal 2025 against -$22 M in 2020.
    • ✗Revenue rose in at least four of the last five years0 of 5Revenue rose in 0 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$1 MNet income -$1 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-3.4%-3.4% against Pharmaceutical's median of 1.8% (74 companies).
    • ✗Return on equity above 15%-58.7%-58.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-3.4%-3.4% in fiscal 2025 against -42.3% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.0×Current ratio 1.03 at the end of fiscal 2025.
    • ✗Debt below equity1.1×Debt to equity 1.12 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year4.9%Diluted shares up 4.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from CV Sciences, Inc.'s statements, beside the median of Pharmaceutical.

CV Sciences, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-3.4%1.8%
Net margin-7.0%-1.5%
Return on equity-58.7%-0.9%
Revenue growth, 3 years a year-5.2%2.5%
Revenue growth-12.2%7.3%
Debt to equity1.12×0.66×

6of 9on the Piotroski tests of financial strength

  • Revenue fell 12.2% against the year before.
  • Net loss of $1 million.
  • Free cash flow was negative: -$1 million.

CV Sciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

CV Sciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue13,78915,70516,00416,20520,04824,42953,69648,24420,679r11,061
Cost of revenue7,0378,5378,91910,65511,43213,42018,60814,3666,190r4,063
Gross profit6,7527,1687,0855,5508,61611,00935,08833,87814,489r6,998
Research and development1221181513071,1852,9435,8771,885724r1,159
Selling, general and administrative7,6229,2409,74512,09025,87730,65846,45121,74616,193r13,130
Selling and marketing2,8033,1663,065———————
General and administrative3,1533,9863,74012,09025,87730,65846,45121,74616,193r13,130
Operating expenses———12,39727,06233,60152,32823,63119,349r20,071r
Operating income−470−2,1903,360−6,847−18,446−22,592−17,24010,247−4,860r−13,074
Interest expense and finance costs517212—60038——153507r1,087
Net interest income———−1,541−140−9.015−153——
Other non-operating income (expense)−479−212−264−1,541———−153−519r−1,068
Income before tax−949−2,4023,096−8,261−15,641−22,601−17,22510,094−5,379r−14,141
Income tax9.0−8.0−6.0−47−87−317−61593−482r0
Net income attributable to shareholders−958−2,3943,102−8,214−15,554−22,284−16,61010,001−4,897r−14,141
Earnings per share, basic-0.01-0.010.02-0.07-0.14-0.22-0.170.11-0.06r-0.27r
Earnings per share, diluted-0.01-0.010.02-0.07-0.14-0.22-0.170.09-0.06r-0.27r
Shares, weighted average (basic)184176154138108100989280—
Shares, weighted average (diluted)1841761541381081009811480r53
Balance sheet
Cash and cash equivalents2784541,3176111,3754,0249,10712,6842,013r782
Receivables4025224317662,0411,1262,1773,3401,507r360
Inventory4,0874,8975,6556,5638,6248,8409,9717,1322,823r2,852
Other current assets3663705353,1902,1462,37210,611585400r0r
Current assets5,1336,2437,93811,13014,18616,86332,36725,4667,935r4,821
Property, plant and equipment3443993795751,7172,8773,6152,8442,084r243
Right-of-use (leased) assets3479416727503,0578,7090——
Goodwill1,015971342002,7882,7882,7882,788r2,788
Other intangible assets7693782511,4853,7303,7663,8013,836r3,872
Non-current assets————————14,77513,771
Total assets6,9627,9279,20012,73618,06630,62552,68736,90222,710r18,592
Accounts payable1,0441,9252,3092,2842,6241,6771,6171,245678r524
Debt due within a year1,262677——3102,174————
Current liabilities5,0006,1096,11513,31414,46114,33613,1964,3923,336r3,149
Long-term debt3870——01,453————
Lease liabilities (non-current)100195818803,4679,5170——
Total liabilities5,4946,1326,29713,51314,52319,41323,5406,7866,329r5,384
Retained earnings−87,939−86,981−84,587−87,689−79,475−63,921−41,637−25,027−35,028r−30,131
Shareholders' equity1,4681,7952,903−7773,54311,21229,14730,11616,381r13,208r
Total liabilities and equity6,9627,9279,20012,73618,06630,62552,68736,90222,710r18,592
Shares outstanding184184162152112101999591r58
Cash-flow statement
Depreciation and amortization1923342359921,153872716519183r1,053
Share-based compensation4972582181,0093,2103,8815,5892,9253,419r2,733
Cash from operating activities−407−8612,253−1,885−7,485−7,300−2,22712,5593,615r−2,054
Capital expenditure−109−1800−35−1,057−1,147r−893−454r−17
Acquisitions, net of cash acquired0−10−1560——————
Cash from investing activities−109−28−1560−35−1,057−1,147−1,244−2,000r853
Shares issued———04,4071930——0
Cash from financing activities33732−1,3911,1214,3703,27447−1,172119r1,740
Exchange-rate effect on cash3.0−6.00———————
Change in cash−176−863706−764−3,150−5,083−3,32710,143——
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where CV Sciences, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.

CV Sciences, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office2 subsidiaries—
🇵🇱 Poland1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at CV Sciences, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$419 K
Mr. Dowling
Other top executives, average
$308 K
the CEO earned 1.4× this
$100 invested is now
—
CV Sciences, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Dowling$419 K$423 K$308 K—
2024Mr. Dowling$458 K$241 K$343 K$100
2023Mr. Dowling$403 K$314 K$273 K$133

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at CV Sciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 8 · Agreement ended 1 · New debt 2 · Unregistered share sale 3 · Shareholder vote 3 · Results announced 11

CV Sciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Agreement ended8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of CV Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2014$1 MPrivate placement after listingUnder $2 million11equitySEC
Nov 2013$3 MNo. 1$2 to $10 million7equitySEC
Jan 2013$5 MIssued in a merger or acquisition$2 to $10 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How CV Sciences, Inc. compares in Pharmaceutical

  • Revenue$14 M · higher than 7% of 324
  • Net margin-15.8% · higher than 16% of 313
  • Revenue growth-12.2% · higher than 12% of 107

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
CV Sciences, Inc.🇺🇸$20 M—-15.8%-12.2%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 7, 2022 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at CV Sciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show CV Sciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about CV Sciences, Inc.? Suggest a correction